Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 4:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 181 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adenocarcinoma of the Prostate Stage III Clear all
Completed Phase 3 Interventional Results available

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

NCT00079001
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
zoledronic acid, placebo, androgen deprivation therapy, GnRH agonist, Calcium supplement, Vitamin D
Drug · Other · Dietary Supplement
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
238
States / cities
Mobile, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 159 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 8, 2026, 4:38 PM EDT
Active, not recruiting Phase 2 Interventional

Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy

NCT04915508
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Hormone Therapy, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 8, 2026, 4:38 PM EDT
Completed Not applicable Interventional

Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer

NCT01117935
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
intensity modulated external beam radiation therapy
Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 8, 2026, 4:38 PM EDT
Recruiting Phase 3 Interventional

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

NCT05946213
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
1,209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2041
U.S. locations
402
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 303 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 8, 2026, 4:38 PM EDT
Completed Phase 2 Interventional Results available

68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer

NCT03113617
View directory record Official record
Conditions
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma, Stage IV Prostate Adenocarcinoma
Interventions
Computed Tomography, Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Laboratory Biomarker Analysis, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
Andrei Iagaru
Other
Eligibility
19 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 8, 2026, 4:38 PM EDT
Not listed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005960
View directory record Official record
Conditions
Pain, Prostate Cancer
Interventions
filgrastim, cyclophosphamide, docetaxel, doxorubicin hydrochloride, pain therapy
Biological · Drug · Procedure
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
6
States / cities
Los Angeles, California • Vero Beach, Florida • Great Neck, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 8, 2026, 4:38 PM EDT
Completed Phase 2Phase 3 Interventional Results available

68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery

NCT02678351
View directory record Official record
Conditions
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
Interventions
68Ga-PSMA-11, Magnetic resonance imaging (MRI), Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 8, 2026, 4:38 PM EDT
Completed Phase 3 Interventional Results available

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

NCT00134056
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
atrasentan hydrochloride, docetaxel, prednisone, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
1,038 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
554
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 378 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 8, 2026, 4:38 PM EDT
Completed Phase 2 Interventional

Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer

NCT00006359
View directory record Official record
Conditions
Prostate Cancer
Interventions
LHRH agonist, antiandrogen, radiation therapy, Brachytherapy boost
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
26
States / cities
Lewes, Delaware • Newark, Delaware • Wilmington, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 8, 2026, 4:38 PM EDT
Completed Phase 2 Interventional

Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer

NCT00002889
View directory record Official record
Conditions
Prostate Cancer
Interventions
flutamide, goserelin, leuprolide acetate, low-LET photon therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
30 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
12
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 8, 2026, 4:38 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT01368588
View directory record Official record
Conditions
Prostate Cancer
Interventions
three-dimensional conformal radiotherapy, intensity modulated radiotherapy, Brachytherapy, Anti-androgen, luteinizing hormone-releasing hormone (LHRH) agonist or antagonist
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
2,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2031
U.S. locations
454
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 351 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 8, 2026, 4:38 PM EDT
Terminated Phase 2 Interventional Results available

Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

NCT00937768
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 8, 2026, 4:38 PM EDT
Active, not recruiting Phase 2 Interventional

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

NCT04777071
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography, Magnetic Resonance Imaging, Bone Scan, Electronic Health Record Review
Procedure · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 8, 2026, 4:38 PM EDT
Terminated Phase 2 Interventional Results available

Perifosine in Treating Patients With Recurrent Prostate Cancer

NCT00058214
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
perifosine, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 8, 2026, 4:38 PM EDT
Completed Phase 1 Interventional

Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy

NCT00305747
View directory record Official record
Conditions
Prostate Cancer
Interventions
BR-DIM
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Oct 8, 2026, 4:38 PM EDT
Withdrawn Not applicable Interventional

Targeted Biopsies in Determining Response in Patients With Prostate Cancer Undergoing High-Dose-Rate Brachytherapy

NCT02597894
View directory record Official record
Conditions
Stage III Prostate Adenocarcinoma
Interventions
Biopsy of Prostate, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 8, 2026, 4:38 PM EDT
Completed Phase 2 Interventional Results available

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer

NCT00589472
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
Bicalutamide, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Therapeutic Conventional Surgery, Vorinostat
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 8, 2026, 4:38 PM EDT
Completed Phase 1 Interventional

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

NCT00045006
View directory record Official record
Conditions
Cancer
Interventions
vorinostat
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 8, 2026, 4:38 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

NCT02849990
View directory record Official record
Conditions
Stage III Prostate Adenocarcinoma AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7
Interventions
Abiraterone Acetate, Apalutamide, Degarelix, Indomethacin, Laboratory Biomarker Analysis, Prednisone
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Oct 8, 2026, 4:38 PM EDT
Completed Phase 2 Interventional Results available

Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer

NCT00450749
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
Interventions
placebo, therapeutic conventional surgery, laboratory biomarker analysis, lycopene
Other · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 8, 2026, 4:38 PM EDT
Completed Phase 2 Interventional Results available

Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients

NCT01882985
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
Docetaxel, Lycopene
Drug · Dietary Supplement
Lead sponsor
University of California, Irvine
Other
Eligibility
21 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 8, 2026, 4:38 PM EDT
Completed Phase 3 Interventional

Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer

NCT00002760
View directory record Official record
Conditions
Prostate Cancer
Interventions
ketoconazole, therapeutic hydrocortisone, Withdrawal of antiandrogen therapy
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 120 Years · Male only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2009
U.S. locations
2
States / cities
San Francisco, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Oct 8, 2026, 4:38 PM EDT
Completed Phase 1 Interventional

GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer

NCT00305669
View directory record Official record
Conditions
Prostate Cancer
Interventions
sargramostim, immunohistochemistry staining method, immunological diagnostic method, laboratory biomarker analysis, conventional surgery, neoadjuvant therapy
Biological · Other · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 8, 2026, 4:38 PM EDT
Completed Phase 2 Interventional

Low-Fat, High-Fiber Diet Compared to a Standard Diet in Treating Patients With Prostate Cancer

NCT00020995
View directory record Official record
Conditions
Prostate Cancer
Interventions
therapeutic dietary intervention
Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
40 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 8, 2026, 4:38 PM EDT